ChemoCentryx

First Quarter 2018
Financial Results Conference Call

May 9, 2018

ChemoCentryx

Forward-Looking Statements

This presentation contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “contemplate,” “believe,” “estimate,” “predict,” “project,” “seek,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements relate to future events or our future financial performance or condition and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described more fully in our periodic reports filed with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC on March 12, 2018, particularly in the sections titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations”. In light of the significant uncertainties in our forward-looking statements, you should not place undue reliance on these statements or regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all. The forward-looking statements contained in this presentation represent our estimates and assumptions only as of the date of this presentation and, except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this presentation.

This presentation also contains estimates, projections and other information concerning our industry, our business, and the markets for our drug candidates, as well as data regarding market research, estimates and forecasts prepared by our management. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information.

ADVOCATE Global Phase III Clinical Trial of Avacopan

Changing the Treatment Paradigm in ANCA Vasculitis

- Two-Arm, Placebo Controlled Study in 300 patients with ANCA Vasculitis
- Sites activated across five continents
- On track to meet target of complete enrollment by mid-2018
- In parallel, EMA accepted CMA application for full review



ADVOCATE

Avacopan – Targeting the Complement Pathway 'Downstream' is Best

Avacopan Advantage:

- Orally administered, small molecule
- Does not block C5b-9 (formation of MAC) leaving host defense mechanism in place



There are concerns regarding biological consequences of inhibiting these 'upstream' elements of complement cascade

Prefer targeting 'terminal damage effectors'

Desirable to block C5aR specifically

Note: The C5L2 pathway important to keep (i.e., don't block C5a, just C5aR)

Patient Enrollment Nears 30% in C3G Registration-Supporting Clinical Trial



Focal Segmental Glomerulosclerosis (FSGS)

- In FSGS, proteinuria (protein in urine) destroys kidney function
- No approved treatments in FSGS, and disease returns in 30-40% of transplant cases
- Previous clinical trial with CCX140 shows it significantly lowered proteinuria (a one year long Phase II trial of diabetic nephropathy)
- CCXI clinical trials underway in two sub-populations of FSGS

5,400 new cases in U.S.
1,000 kidney transplants / year
In 30-40% of transplant patients, FSGS returns

CCR2 Inhibition Increased Podocyte Density in 'FSGS' Mice



- Brown 'spots' are cell nuclei detected with an antibody to WT-1, a podocyte nuclei protein
- Panels show cross section of a kidney glomerulus (roughly circular in this 2 dimensional view)
- The right panel is a typical glomeruli from an FSGS mouse treated with CCR inhibitor for 2 weeks; versus placebo treatment on left

ChemoCentryx

Extending the Reach of Avacopan into Neutrophil Driven Disease Hidradenitis Suppurativa (HS)

- Painful progressive disabling disease causes keloids, contractures, immobility
- Avacopan selectively targets C5aR, implicated in HS
- Potential for greater efficacy over other approaches
- Adalimumab only moderately effective, but sales approach $1BN / year
- Planning clinical trials for 2018

ChemoCentryx

Q1 2018 Financial Results – March 31, 2018

- Cash and investments - $177.1 million
- Total shares outstanding – 49.1 million
- Consolidated statement of operations –

	Three Months Ended March 31,	
	2018	2017
	(unaudited)	
Condensed Consolidated Statements of Operations Data:		
Revenue:		
Collaboration and license revenue	$ 9,546	$ 8,230
Total revenue	9,546	8,230
Operating expenses:		
Research and development	14,742	9,970
General and administrative	4,660	4,573
Total operating expenses	19,402	14,543
Loss from operations	(9,856)	(6,313)
Total other income, net	439	317
Net loss	$ (9,417)	$ (5,996)

Key Takeaways for the Quarter

- Running multiple registration-supporting trials simultaneously:
  - Phase III ADVOCATE trial enrollment surpasses 85% of target
  - Patient enrollment nears 30% in avacopan for C3G
  - Launched trials of CCX140 in two sub-populations of primary FSGS
- Expanding into orphan dermatological disease:
  - Planning underway for clinical trials of avacopan in HS
  - CCR6 inhibitor for GPP (Generalized Pustular Psoriasis)
- Strong cash position